Rigel Pharmaceuticals announced that final Phase 3 trial data for GAVRETO (pralsetinib) as a first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC) will be presented at ASCO 2026, showing improved progression-free survival and response rates over standard care. Additionally, data from Phase 1/2 trials of pralsetinib in RET-altered thyroid cancer and real-world evidence supporting REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia (AML) were presented. These findings highlight the clinical relevance of Rigel's oncology portfolio and suggest olutasidenib may be an effective post-venetoclax therapy for AML patients. The presentations at ASCO and EHA 2026 will further inform treatment strategies for these difficult-to-treat cancers.
Carahsoft Technology Corp. is hosting the Annual GovExperience Summit on June 2, 2026, in Reston, Virginia, focusing on improving government service delivery and customer experience through emerging technologies. The event gathers leaders from federa...
Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo respon...
Anthropic has confidentially submitted a draft registration for an IPO, entering the public market race shortly after SpaceX's filing. While SpaceX focuses on space infrastructure and satellite communications, Anthropic offers investors exposure to f...
This week could be the busiest for IPOs since 2021, with five companies going public that touch on popular Wall Street themes like quantum computing, defense, digital advertising, AI infrastructure, and energy. Notable IPOs include Liftoff Mobile, Ap...
As summer begins, North Texas faces a surge in child hunger due to loss of school meals. WFAA, North Texas Food Bank, and Tarrant Area Food Bank are hosting the Nourish North Texas Telethon on June 11 to raise funds for at least one million meals for...
